Anti-HER2 Therapies in Breast Cancer: Adjuvant and Neodjuvant

Anti-HER2 Therapies in Breast Cancer: Adjuvant and Neodjuvant

0% Complete

Course Overview

NA

Course Content

Course Details

Duration
0.00 hour
Released
May 14, 2025
Last Review
May 14, 2025
Expires
May 14, 2028

Objectives

NA

Target Audience

NA

Faculty & Disclosure

Faculty

Michel Velez, MD

Disclosure

Michel Velez, MD discloses no such relationships exist

Accreditation

NA